This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sabrina W. Yum, MD; Alan I. Faden, MD

Arch Neurol. 1990;47(3):277-281.

Abstract
• Both N-methyl-D-aspartate (NMDA)-receptor antagonists and opiate-receptor antagonists have been shown to limit tissue damage after ischemic central nervous system injury. We compared the neuroprotective effects of the noncompetitive NMDA-receptor antagonist MK-801 and the opiate-receptor antagonist nalmefene in a model of global spinal cord ischemia and reperfusion in unanesthetized rabbits. MK-801 (1 mg/kg) or nalmefene (0.1 mg/kg) was administered intravenously 5 minutes after reperfusion. MK-801 treatment and nalmefene treatment each significantly improved the neurologic and histologic outcome compared with saline controls. Differences in these outcome measures between MK-801 treatment and nalmefene treatment did not reach statistical significance. Our results are consistent with the hypothesis that multiple factors, including endogenous opioids and excitatory amino acids, contribute to the secondary tissue injury after central nervous system ischemia. These data also provide further evidence that therapeutic interventions with opiate-receptor antagonists or NMDA antagonists may be beneficial in limiting neurologic dysfunction after ischemic brain or spinal cord injury.

Author Affiliations
From the Center for Neural Injury, Department of Neurology, University of California, San Francisco, and the Department of Veterans Affairs, San Francisco.

Footnotes
Accepted for publication July 11, 1989.

Reprint requests to the Neurology Service (127), Department of Veterans Affairs, 4150 Clement St, San Francisco, CA 94121 (Dr Faden).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Retrograde perfusion with a sodium channel antagonist provides ischemic spinal cord protection
Gangemi et al.
Ann. Thorac. Surg. 2000;69:1744-1748.
ABSTRACT | FULL TEXT  

Cervene (Nalmefene) in Acute Ischemic Stroke : Final Results of a Phase III Efficacy Study
Clark et al.
Stroke 2000;31:1234-1239.
ABSTRACT | FULL TEXT  

Selective protection of gray and white matter during spinal cord ischemic injury
Follis et al.
Ann. Thorac. Surg. 1999;67:1362-1369.
ABSTRACT | FULL TEXT  

Prevention of Spinal Cord Injury After Repair of the Thoracic or Thoracoabdominal Aorta
Mauney et al.
Ann. Thorac. Surg. 1995;59:245-252.
ABSTRACT | FULL TEXT